

Takeda Canada, Inc.:

Striving Toward Better Health for Individuals and Progress in Medicine



A new name on the Canadian pharmaceutical landscape.

Takeda Canada, Inc. was established on April 1, 2009 as part of a significant global expansion by Takeda Pharmaceutical Company Limited, a world-class pharmaceutical company with a nearly 230 year heritage. Takeda is the largest pharmaceutical company in Japan and one of the top 20 pharmaceutical companies worldwide.

Headquartered in Mississauga, Ontario, the Canadian office is in close proximity to a sophisticated talent pool, modern healthcare system, leading medical centres, thriving biotechnology industry, and tremendous scientific expertise and innovation.

Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. One of the first steps for Takeda Canada is to tailor strategies and activities to the diverse needs of Canadian stakeholders. Canada is a dynamic country with a broad array of geography, culture and healthcare systems. The solutions and products Takeda provides will help meet the diverse and changing needs of its partners and customers.

Takeda's basic management philosophy prescribes that all of its corporate activities are based on the highest levels of integrity, fairness, honesty and perseverance. Takeda strives to be a valued partner to its stakeholders and to act as ethical, dedicated, community-focused, corporate citizens.

With this in mind, Takeda Canada's goal is to bring important medicines to Canadians who need them. Takeda Canada is focused on bringing a number of therapeutic options to Canadians in the coming years in the areas of diabetes, cardiovascular disease, oncology, gastroenterology, neurology and other conditions.

Takeda markets products in 90 countries worldwide.

A company with medicines to help treat a variety of diseases, Takeda markets its products in more than 90 countries worldwide and accomplishes this through the integration of its global operations. As an R&D-driven pharmaceutical company, Takeda aspires to create a stream of new medicines and work to maximize the potential of these products to serve its customers around the world. This will be accomplished through close cooperation among marketing, production, development, research and alliances.



Group photo at the new Takeda Canada office.

Takeda Canada will benefit from the tremendous resources supporting it in its North American and global headquarters. These resources will enable Takeda Canada to accelerate growth in Canada by leveraging the infrastructure, systems and R&D pipeline across Takeda's global organization. This approach will allow Takeda Canada to potentially launch six or more products over the next four years.

What Takeda Canada has done so far

Takeda Canada has made significant achievements in its first year and it plans to sustain and build on that momentum. In the first year alone, Takeda Canada:

- Established its Canadian headquarters;
- Reacquired the commercial rights to Type 2 diabetes treatment ACTOS® (pioglitazone HCI), reinforcing Takeda's presence in Canada among physicians and patients;
- Submitted multiple New Drug Submissions into Health Canada across a range of therapeutic areas.

Moving forward, Takeda Canada will continue to grow its home-office team, while adding a national sales force to market multiple new treatments to Canadians. Takeda plans to partner with scientists and other experts across Canada to further identify ways to serve the unmet needs of healthcare providers and patients in Canada.

Takeda Canada joins more than 19,000 Takeda employees around the world who strive to bring important medicines to those who need them. Takeda Canada will build on its long history as a committed, ethical, corporate citizen by forging strong, collaborative partnerships with its local community in the areas of education, advocacy and healthy lifestyles.

